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Abstract: Two G-quadruplex forming oligonucleotides [d(TG4T)4 and d(TG6T)4] were selected as 
two tetramolecular quadruplex nanostructures because of their demonstrated ability to be modi-
fied with hydrophobic molecules. This allowed us to synthesize two series of G-quadruplex con-
jugates that differed in the number of G-tetrads, as well as in the terminal position of the lipid 
modification. Both solution and solid-phase syntheses were carried out to yield the corresponding 
lipid oligonucleotide conjugates modified at their 3′- and 5′-termini, respectively. Biophysical 
studies confirmed that the presence of saturated alkyl chains with different lengths did not affect 
the G-quadruplex integrity, but increased the stability. Next, the G-quadruplex domain was added 
to an 18-mer antisense oligonucleotide. Gene silencing studies confirmed the ability of such G-rich 
oligonucleotides to facilitate the inhibition of target Renilla luciferase without showing signs of 
toxicity in tumor cell lines. 
Keywords: antisense oligonucleotides; circular dichroism; G-quadruplex; gene delivery; gene 
transfection; lipids; luciferase; nucleic acid conjugates; solid-phase; solution-phase 
 
1. Introduction 
G-quadruplexes are nucleic acid structures constituted by two or more G-quartet 
motifs held together by Hoogsteen and π-π stacking interactions. In addition, these 
structures are stabilized by monovalent cations (Na+ and K+, mainly). G-quadruplexes 
may be parallel, antiparallel or even hybrid structures that differ according to the type of 
loops and the G-tetrad strands orientation [1]. G-quadruplexes were observed for the 
first time in the early 1900s and they were characterized by x-ray diffraction in the sixties 
[2]. Nowadays, applications based on G-quadruplex are many and diverse, ranging from 
diagnostic tools, biosensing and medicine [3–5]. In addition G-quadruplex structures 
have been visualized in human cells [6], being present at the end of the chromosomes 
(telomeres) as well as in some regions of the genome like 5′-UTR regions and oncogene 
promoters (e.g., c-kit, bcl-2 and c-myc), emerging as attractive targets for cancer therapy 
[5]. In this regard, human chromosomal DNA contains single repeated guanine-rich 
residues (TTAGGG) at the telomeres. These areas have variable lengths, controlled by 
telomerases, which diminish with the number of cell divisions. In contrast, cancer cells 
have long telomeres providing uncontrolled cellular proliferation [7,8]. Therefore, ap-
propriately designed G-quadruplex ligands have played a crucial role in recognizing 
such structures, promoting telomere damage and therefore favoring cell death [3]. 
The rapid growth of nanotechnology in the last decades has allowed the design of a 
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plethora of nanostructures for medicine opening up novel and promising alternatives to 
classical treatments [9]. In this regard, the usage of liposomes, niosomes and polymers 
has generated great interest in therapy due to their nanometric size, easiness of produc-
tion, storage, as well as improvements in the transport of certain small therapeutic drugs 
and macromolecules [10–12]. In addition, the preparation of second and third generation 
of such nanovehicles has introduced novel features such as the enhancement of half-lives 
in bloodstream and effectiveness by tailoring with specific ligands, antibodies or ap-
tamers to favor targeted delivery [13,14]. 
While liposomes and other colloidal formulations have been widely used in nano-
medicine with success, other strategies involving nanometric sizes have also become 
promising tools in therapy [15]. DNA nanotechnology represents an emerging approach 
that relied on employing synthetic building blocks with the aim of creating nanoscale 
architectures precisely with various applications, including biosensing, genomics, pro-
teomics, drug delivery and gene therapy, among others [9,16–19]. Multiple 
self-assembling nanoparticles and bio-inspired DNA materials exhibiting different 
shapes (e.g., cubes, octahedra, icosahedra, and tetrahedra), including DNA origami have 
been properly engineered in order to increase their selectivity, efficiency, prolong stabil-
ity and reduce the side effects of classical therapeutic approaches [18,20]. The construc-
tion of this variety of nanostructures, acting as nanocarriers, has made important con-
tributions to developing strategies in many in vitro and in vivo models with the aim to 
deliver small drug therapeutics (e.g., Doxorubicin [21], 5-fluoro-2-deoxyuridine (5-FdU) 
[18], among others), RNAi therapeutics [20] or CpG oligonucleotides [22]. 
Aptamers, with many of them exhibiting DNA or RNA G-quadruplex motifs, have 
been used as diagnostic platforms and targeting ligands to facilitate drug delivery pro-
cesses [23,24]. Other simpler G-quadruplex forming oligonucleotides like Tetrahymena 
telomere dTG4T, which is able to self-assemble to give parallel tetramolecular structures, 
have been used as a G-quadruplex model in many applications involving binding pro-
cesses and the identification of new ligands for anticancer therapy [25]. Interestingly, 
modifications of this G-quadruplex have also been reported by introducing carbohy-
drates [26] and cationic amino acids [27] using covalent strategies or the formation of 
supramolecular dendrimers. The use of [d(TG4T)]4 quadruplex as a nanostructure to 
transport biomolecules has been scarcely investigated [27]. Our group recently proposed 
the use of positively charged nanoconstructs based on the Tetrahymena telomere sequence 
dTG4T with the aim to favor the delivery of an antisense (AS) oligonucleotide in human 
cancer cells. To do so, our strategy relied on chemically introducing a series of cationic 
amino acids at the 3′- or 5′-termini of the AS oligonucleotide. This synthetic strategy al-
lowed us to obtain stable parallel cationic G-tetrads that were able to transport and in-
ternalize AS oligonucleotides inside cells and therefore inhibit the production of the lu-
ciferase reporter protein [27]. In addition, lipid-oligonucleotide conjugates forming 
G-quadruplex (lipoquads) have been described by some of us to be potent antiviral 
compounds against human immunodeficiency virus (HIV-1, HIV-2) [28] and hepatitis C 
virus (HCV) by inhibiting viral entry [28,29]. These antiviral oligonucleotides formed 
parallel tetramolecular structures with 6 G’s and carried cholesterol or linoleyl moieties 
at the 3′-end [28,29]. In order to gain further insight into the application of such supra-
molecular scaffolds in gene silencing, we have extended these studies by modifying the 
3′- or the 5′-termini of such G-quadruplex nanostructure with two saturated lipids of 
different lengths. To do so, two synthetic methodologies involving solution and sol-
id-phase strategies were accomplished to afford a series of hydrophobic series containing 
two supramolecular G-tetrad scaffolds like [d(TG4T)]4 and [dTG6T]4, as well as an 18-mer 
AS oligonucleotide (Figure 1). In this article, the synthesis and biophysical characteriza-
tion of such hybrid nanostructures, including their effect on cellular viability and use in 
antisense therapy, were assessed. 




Figure 1. Two series of G-quadruplex forming oligonucleotide conjugates containing four and six 
G-quartets were engineered: (A) a threoninol-based building block modified with two lipids of 
different length (C8 and C14) was introduced covalently at the 3′-termini of a G-rich oligonucleo-
tide sequence and (B) two hydrocarbon lipids of different length (C8 and C14) were introduced at 
the 5′-termini of a G-rich oligonucleotide sequence using a carboxylate linker. An 18-mer phos-
phorothioate (Luc) oligonucleotide was also attached at the 5′-termini of the G-rich sequence oli-
gonucleotide. 
2. Results and Discussion 
Chemical modification of oligonucleotides with hydrophobic residues represents a 
useful strategy to modulate the intrinsic properties of nucleic acids [30]. Thus, cationic 
lipids [31,32], neutral lipids [33,34] and fatty acids [35] have been attached covalently ei-
ther at the 3′- or 5′-ends in order to improve the cellular uptake, stability and pharmaco-
kinetic properties of AS oligonucleotides, small interference RNAs (siRNAs) and mi-
croRNAs (miRNAs) [36]. In this regard, very promising results involving lipid oligonu-
cleotide conjugates (LOCs) have been obtained in vivo, leading to successful results 
when we launched clinical trials [37].  
Recently, some research groups have synthesized modified lipid G-quadruplexes 
showing their similarities to lipid-based micelles in size and proving their efficiency as 
supramolecular scaffolds to promote cargo release [38–40]. Inspired by these results and 
by our previous findings based on delivering ASOs using G-quadruplex nanostructures 
modified with cationic amino acids [27], we envisaged engineering two series of 
G-quadruplex forming oligonucleotides varying the number of guanosines in the oligo-
nucleotide chain (TG4T and TG6T) and containing two saturated lipids of different length 
(C8 and C14), which were introduced at either the 3′- or 5′-termini of the G-rich oligonu-
cleotide chain. To do so, two synthetic strategies were accomplished: (i) a threoninol de-
rivative [41] bearing the corresponding hydrophobic residues was obtained using solu-
tion-phase strategies in order to modify the 3′-termini and (ii) CPG solid supports were 
properly modified with a carboxylate group using solid-phase strategies that enabled the 
introduction of the two selected amino lipids (octylamine and tetradecylamine) at the 
5′-end.  
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2.1. Synthesis of Lipid Threoninol Derivatives and Preparation of Lipid Oligonucleotide 
Conjugates (LOCs) with G-Rich Sequences 
We envisaged the chemical modification of our starting material with two hydro-
carbon alkyl chains (C8 and C14) that could be tackled previously by activating 
Fmoc-Lys(Boc)-OH with N-hydroxysuccinimide (NHS) in standard conditions affording 
the intermediate (1) (Figure 2). This activated molecule proceeded smoothly when re-
acted with L-threoninol, yielding the expected protected threoninol derivative (2) in good 
yield (75%). Subsequent Boc deprotection under acid conditions (10% TFA in CH2Cl2) 
afforded a rapid access to nucleophilic addition of the amine derivative with the corre-
sponding acyl chlorides of different lengths. To avoid undesirable O-acetylated deriva-
tives, we pursued a synthetic approach favoring the formation of N-acetylated com-
pounds following the Schotten-Baumann conditions (50% w/v aq NaOAc in THF) [42]. 
This biphasic strategy led to the formation of threoninol derivatives (3) and (4), modified 
with the C8 and C14 saturated alkyl chains in good yields (97 and 78%, respectively). The 
last step, prior to Controlled Pore Glass (CPG) functionalization, was relied on protecting 
the threoninol’s primary alcohol with a trityl (Tr) protecting group. This bulky protecting 
group is essential to start up automatic DNA synthesis and therefore to synthesize the 
corresponding oligonucleotide sequences. We selected the Tr group instead of the 
standard DMT group because DMT derivatives were not stable enough in silica gel. Iso-
lation of the resultant trityl threoninol derivatives (5) and (6) were challenging due to 
their hydrophobicity, affording overall low yields after purification by flash chromatog-
raphy (24 and 53% for 5 and 6, respectively). Finally, CPG functionalization took place 
efficiently with the elaboration of the corresponding hemisuccinate derivatives obtained 
from the opening of succinic anhydride mediated by DMAP and alcohols (5) and (6) in 
the solution-phase. Finally, a coupling reaction between the CPG beads’ amine groups 
and hemisuccinate derivatives [43] allowed us to functionalize the polymer supports and 
thus afforded the corresponding functionalized CPG-7 (37.6 μmol·gr−1) and CPG-8 (23.0 
μmol·gr−1). Taking both CPG beads in our hands, it allowed us to initiate the solid-phase 
oligonucleotide synthesis and thus modifying the 3′-termini of two G-rich 
proof-of-concept sequences such as d(TG4T) and d(TG6T). Finally, the corresponding li-
pid oligonucleotide conjugates were detached from the solid support under ammonia 
treatment at 55 C affording four threoninol-based LOCs (11–14), which were purified 
according to DMT-on protocols and characterized by MALDI-TOF spectrometry (Table 
1). 
 
Figure 2. Synthetic route devised to obtain CPG solid supports modified with octyl and tetradecyl alkyl chains and lipid 
oligonucleotide conjugates (LOCs). Reagents and conditions: a. NHS, EDCI, DCM, r.t.; b. (1), DMF, r.t., overnight; c. (i) 
DCM:TFA 10%, r.t., 30 min; (ii) AcONa 50% w/v, THF:H2O (1:1), RCOCl (R = octyl chloride or tetradecanoyl chloride, r.t., 
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overnight; d. TrCl, DIPEA, pyridine, 45oC, overnight; e. CPG functionalization; f. (i) aq. NH3 (32%), 55 ºC, overnight; (ii) 
HPLC purification; (iii) AcOH 80%, 30 min, r.t.; (iv) NAP-10. 
2.2. Preparation of Lipid Oligonucleotide Conjugates (LOC) hybrids containing the Luc sequence  
The appropriate design and selection of antisense oligonucleotide sequences is key 
to achieve successful results in antisense therapy. We decided to use an 18-mer antisense 
oligonucleotide of sequence 5-CGTTTCCTTTGTTCTGGA-3 (Luc) as a model [44] to 
evaluate the feasibility of our nanoconstructs to bind to the Renilla luciferase mRNA se-
quence specifically.  
Two LOC series containing two distinct G-rich scaffolds [d(TG4T) and d(TG6T)] were 
prepared depending on the position of the lipid modification (Figure 3). Thus, having 
CPG-7 and CPG-8 in our hands, the first set of phosphorothioate oligonucleotide conju-
gates containing a lipid modification (either octyl, C8 or tetradecyl, C14) and the Luc se-
quence at the 5′-end, respectively, were obtained (15–18) in accordance with standard 
DNA synthesis protocols. Alternatively, a second family of phosphorothioate lipid oli-
gonucleotide antisense conjugates containing the same G-rich scaffolds, as described 
before, was devised by introducing two hydrophobic amino lipid tails with the same 
length (C8 and C14), as introduced above, but at the 5′-termini of the Luc sequence. To do 
so, a protected carboxylate modifier phosphoramidite acting as a spacer was introduced 
in order to modify the 5′-antisense sequence termini and assist the final conjugation be-
tween the two selected amino lipids and the DNA sequence on solid-phase. After manu-
ally removing the 2-chlorotrityl protecting group under acid conditions (2% TCA), the 
amide-bond formation took place prior to activating the carboxylic group with a mixture 
of PyBOP and HOBt (1:1) in an organic solvent (DMF) [45]. Finally, the resultant 
5′-oligonucleotide conjugates containing octylamine and tetradecylamine (21–24) were 
detached from CPG solid supports under standard basic conditions and the yield of the 
reaction was analyzed by HPLC, which ranged from 60% to 80%. All LOC containing 
both d(TG4T) and d(TG6T) building blocks (LOC_(15–18) and LOC_(21–24)) were isolated 
according to well established protocols, purified by semi-preparative HPLC and charac-
terized by MALDI-TOF mass spectrometry (Table 1). 
 
Figure 3. Preparation of (i) LOC containing threoninol-based hydrocarbon alkyl chains and a Luc 
oligonucleotide at the 3′- and 5′-termini of a G-rich oligonucleotide sequence (TG4T and TG6T), re-
spectively (Group A); (ii) LOC containing a Luc oligonucleotide at the 5′-termini of a G-rich oligo-
nucleotide sequence (TG4T and TG6T) and two hydrocarbon alkyl chains at the 5′-termini of a Luc 
oligonucleotide (Group B). Reagents and conditions: a. DNA synthesis and amide formation 
(5′-modification only); b. (i) aq. NH3 (32%), 55 ºC, overnight; (ii) HPLC purification; (iii) AcOH 80%, 
30 min, r.t.; (iv) NAP-10. 
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Table 1. Sequences and characterization data (MALDI-TOF mass spectrometry) of oligonucleo-
tides. 







T1/2 Na+ (oC)d 
9 TG4T PO unmod. 1863 1860 59.2e 
10 TG6T PO unmod. 2521 2519 >80 
11 TG4T_C8 PO 3′_Thr_C8a 2284 2281 >80 
12 TG4T_C14 PO 3′_Thr_C14a 2368 2366 >80 
13 TG6T_C8 PO 3′_Thr_C8a 2942 2940 >80 
















PS/PO 3′_Thr_C14b 8837 8838 - 
19 Luc-TG4T PS/PO unmod. 7672 7365f - 
























PS/PO 3′_Thr_C8a 8546 8548 - 
Luc sequence: d(5-CGTTTCCTTTGTTCTGGA-3); unmod: unmodified; PO: phosphodiester; PS: 
phosphorothioate (underlined); F: fluorescein. aOligonucleotide conjugates containing hydropho-
bic threoninol-based derivatives with distinct length of hydrocarbon alkyl chains (C8 or C14); bLOC 
containing the Luc sequence at the 5′-end of the G-rich sequence; cLOC containing two hydrocarbon 
alkyl chains of distinct length (C8 or C14) at the 5′-end of the Luc sequence; dapparent melting 
temperature (non-equilibrium) of the G4 constructs in 10 mM sodium cacodylate buffer with 0.15M 
NaCl (pH 7.2) with a heating rate of 1.0 ºC min−1; eRef. [27]; fthe fragment [GGGGT_Luc]+ is ob-
served [27]; g[M+ K+]; h[M-octylamide]. 
2.3. G-quadruplex Formation and Biophysical Characterization 
G-quadruplex (G4) forming oligonucleotide conjugates were prepared and charac-
terized (Figure 4 and Figure 5) from their lipid oligonucleotide counterparts (11–24) in 
the presence of two buffer solutions: 10 mM sodium cacodylate buffer (pH 7.2) supple-
mented with 0.11 M NaCl [46] and 10 mM phosphate buffer solution (pH 7.4). In this 
regard, sodium cacodylate buffer was used to dissolve G-rich oligonucleotide conjugates 
(11–14), and upon the addition of NaCl, favored their self-assembling to form the ex-
pected G4 nanostructures G4_(11–14) bearing four and six G-quartets, respectively. The 
quadruplex formation of unmodified and 3′-lipid constructs (9–14) were visualized after 
running and staining a native polyacrylamide gel in 1X TBE supplemented with 100 mM 
KCl. As illustrated in Figure 5A, the presence of the lipids (C8 and C14) at the 3′-termini 
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did affect either the formation or the stability of the aforementioned quadruplexes ob-
taining the expected nanostructures, exclusively. Octathymidylate (T8) oligonucleotide 
was used as a negative control and for this reason the gel was stained with “stains-all”. 
To further study the contribution of hydrophobic residues on the G4 telomeric stability, 
circular dichroism, CD melting analyses and the Thioflavin T-displacement assay were 
carried out taking unmodified quadruplexes G4_9 and G4_10 as controls. The unmodi-
fied tetramers [d(TG4T)]4 and [d(TG6T)]4 are four-stranded parallel structures that typi-
cally display two bands; one positive at 264 nm and another negative at 240 nm according 
to standard CD spectra [47]. This behavior was also observed in our G4-conjugates (11–
14) making clear that hydrophobic 3′-threoninol derivatives did not alter G4 formation at 
room temperature, as observed in other modified G4 nanostructures [27] (Figure 5B). 
Additionally, Thioflavin T-displacement assay [48,49] was used to confirm the presence 
of the G-quadruplex structures in 9–14 using a single-stranded T-rich oligonucleotide 
(T8) as a negative control. Thus, equimolecular amounts of ThT acting as a fluorescent 
dye, unmodified G-quadruplex-forming oligonucleotides (9, 10), and G-quadruplex 
forming oligonucleotide conjugates (11, 13, 14) were mixed separately with increasing 
concentrations of ThT (Figure 5C). As expected, ThT probe emitted fluorescence when 
recognized and bounded to our pre-formed G4-constructs thus confirming the presence 
of lipids attached at the 3′-termini did not disturb the G-quadruplex formation. 
 
Figure 4. G-quadruplex forming oligonucleotide conjugates prepared in this study. A. Lipid threoninol-based modifica-
tions were introduced at the 3′-termini of the G-rich sequence and B. Lipid amino lipids were introduced, modifying the 
5′-terimni of the G-rich sequence. 
Thermal denaturation experiments of modified quadruplexes (11–14) were assessed 
in 10 mM sodium cacodylate, 110 mM NaCl buffer recording the ellipticity at 263 nm as a 
function of the temperature from 20 to 80 C (Figure 5D). Petraccone et al. already ob-
served that a greater number of G-quartets present in telomeric sequences produced an 
increase of their thermal stability [47]. This behavior was also observed here, when the 
apparent melting temperatures (T1/2) of the prepared tetramers (11–14) were determined. 
It is worth mentioning that G4 tetramers are not usually found in a thermodynamic 
equilibrium during unfolding processes as their association/dissociation rates are usually 
slow [50]. In this regard, when the unmodified tetramer G4_9 was heated up at 80 C with 
a heating rate of 1.0 C min−1, negative and positive bands at 240 and 263 nm, respectively, 
reduced in intensity, recording an apparent melting temperature of 59.2 C [27]. Inter-
estingly, we found the presence of hydrophobic threoninol-based derivatives in G4 con-
structs containing their four and six G-quartets modified at the 3′-termini had a mean-
ingful impact on the mechanism that governs G4 dissociation processes. In this sense, 
while TG4T had a clear melting profile at around 59 ºC [27], the 3′-octyl derivative 
TG4T_C8 (11) showed only a minor decrease in the band intensity at 80 C. In the other 
3′-lipid G-quadruplex studied (TG4T_C14 (12), TG6T_C8 (13) and TG6T_C14 (14),) we did 
not observe any changes in the CD spectra up to 80 C (Figure 5C and Table 1), indicating 
that the G-quadruplex formed was very stable. 
Naively, we tried to confirm the formation of parallel quadruplex structures con-
taining Luc oligonucleotide by CD. Despite showing the negative band at 240 nm, the 
addition of 18 bases antisense sequence did not allow for the valuable CD spectral data as 
the additional 18 bases present CD signals near the positive band of parallel quadruplex 
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at 264 nm interfering the analysis of the bands. For this reason, the formation of the 
G-quadruplex in the oligonucleotides carrying the luciferase sequence was visualized in 
native PAGE gels (Figure S1, Supplementary information). Curiously, we observed that 
G-rich conjugates containing Luc oligonucleotide displayed a different trend when lipids 
were introduced either at 3′- or 5′-termini. While antisense G-quadruplex conjugates 
containing hydrophobic residues at the 3′-termini showed the G-quadruplex secondary 
structure practically was unchanged in most cases, this was the opposite in the case of 
lipid modifications (C8 and C14) introduced at the 5′-termini. Unexpectedly, native 
PAGE gels showed mixtures of two bands that were assigned for the mobility to the 
monomeric form and the G-quadruplex after being stained with SYBR green (Figure S1, 
Supplementary information). As a general trend, the presence of lipids at the 5′-end dis-
rupted G-quadruplex formation while most of the 3′-modified G-rich sequences main-
tained the band assigned to G-quadruplex as the major band. The unmodified G-rich 
sequences 19 (Luc-TG4T) and 20 (Luc-TG6T) showed a different behavior. The major band 
of Luc-TG4T (19) was assigned to monomer while the major band of oligonucleotide 
Luc-TG6T (20) was assigned to quadruplex. Likewise, ThT assays were also assessed to 
further confirm the results observed in the PAGE native gel. Following the same exper-
imental protocols carried out in the case of G-quadruplex structures described above, 
representative antisense G-quadruplex-forming oligonucleotide conjugates containing 
both lipid modifications and Luc oligonucleotide G4_(15, 16) and controls G4_(9, 10 and 
19) and Luc oligonucleotide alone were mixed separately with increasing concentrations 
of ThT (see Supplementary material). Surprisingly, ThT dye bounded to our sin-
gle-stranded Luc phosphorothioate oligonucleotide that emitted significant fluorescence 
intensities (Supplementary information), but slightly less than our pre-formed antisense 
G4-quadruplex conjugates selected in this study, except for G4_19, which obtained 
maximum fluorescence intensity values. The affinity constants and G-quadruplexes are 
also listed in Table S1 (see Figure S3; Supplementary information).  
 
Figure 5. Native PAGE analysis, circular dicrhoism (CD), CD melting spectra, and Thioflavin T (ThT)-displacement assay 
of G-quadruplex forming oligonucleotides G4_(9–14). (A) Native 20% polyacrylamide gel electrophoresis analysis of 
G-forming oligonucleotide conjugates (9–14) in 1X PBS supplemented with 100 mM KCl. A mixture of bromophenol blue 
and xylene cyanol was used as a marker. T8 is an oligonucleotide containing 8 thymidines that was used as a negative 
control as it is unable to form a quadruplex and indicate the position of a single-stranded 8-mer. (B) CD spectra measured 
at 20 C showing positive and negative bands at 264 and 240 nm, respectively. This confirms the presence of a parallel 
G-quadruplex construct. G-constructs were obtained in 10 mM sodium cacodylate, 110 mM NaCl buffer; (C) ThT dis-
placement assay shows the emitted fluorescence of ThT probe when bounded to G-quadruplex structures. A T-rich oli-
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gonucleotide (T8) was used as a negative control; (D) CD melting spectra at several temperatures ranging from 20 to 80 C 
with a heating rate of 1.0 C min−1. All conjugates showed remarkable stabilities except, for G4_11, which had a band in-
tensity that was slightly reduced. 
2.4. In vitro Transfection Studies 
After the biophysical characterization, G-constructs containing a phosphorothioate 
oligonucleotide (Luc) as an additional pendent group were engineered in order to make 
these nanostructures as potential vehicles to be used in antisense therapy.  
Some G-quadruplexes, particularly those pre-formed in the presence of potassium, 
have proved their efficacy as proliferation inhibitors inducing apoptosis in HeLa cervical 
carcinoma cells at 10 μM as a final concentration in a single dose [51]. Before carrying out 
gene silencing studies, the effect of our modified G-rich oligonucleotides on cellular via-
bility was first assessed. Cytotoxicity analysis was studied using the MTT colorimetric 
assay [52]. As shown in Figure 6, two sets of antisense G-rich oligonucleotides were 
tested, depending on the number of G-tetrads these conjugates were made up of and the 
position of the lipid modification (3′- or 5′-) (15–18 and 21–24). Two unmodified controls 
containing exclusively Luc oligonucleotide and four Gs [27] and six Gs (20) were also 
used. Four increasing concentrations of the corresponding antisense conjugates were 
studied (60, 120, 300 and 600 nM), which did not have any influence on the proliferation 
process of HeLa cells after 24 h-incubation. As a consequence, cellular viabilities ranging 
from 80% and 100% were obtained when compared to non-treated cells (Blank), implying 
that these G-rich oligonucleotides could be used in subsequent gene silencing studies. In 
addition, the potential toxicity of these compounds on a non-cancerous cell line (HEK293) 
was assessed using the same oligonucleotide concentrations, as described above (60, 120, 
300 and 600 nM). The results showed cellular viabilities ranging from 80%–100%, con-
firming that our compounds were non-toxic to HEK293 cells (Figure S2, Supplementary 
information).  
 
Figure 6. Cytotoxicity analysis of antisense conjugates containing four Gs (A, C) and six Gs (B, D). A lipid thre-
oninol-based modification at the 3′-termini were introduced (A and B); a lipid modification (C8, C14) was introduced at 
the 5′-termini (C and D). Four concentrations of antisense conjugates, ranging from 60 nM to 600 nM, were used. All an-
















































concentration (nM) 60 120 300 600 60 120 300 600
sample 16





































B. 3’-Lipid antisense threoninol-based G-quadruplex conjugates
(Luc-TG6T-3’-Thr)  

































C. 5’-Lipid antisense G-quadruplex conjugates (5’-lipid-Luc-TG4T)
concentration (nM)
sample
60 120 300 600 60 120 300 600
17




















































60 120 300 600
23
Int. J. Mol. Sci. 2021, 22, 121 10 of 24 
 
 
Having established that our G-rich antisense oligonucleotides 17–24 did not com-
promise the cellular viability of HeLa cells, the ability of such oligonucleotides to trans-
fect cells and knockdown Renilla luciferase mRNA was studied. Transfection experi-
ments in the presence of lipofectamine and without using this commercially available 
cationic lipid were carried out. Recently, our group confirmed that G-quadruplex con-
structs, modified with a series of cationic amino acids at the 3′-termini, were able to re-
duce luciferase protein expression thereby confirming these nanostructures did not dis-
rupt any AS oligonucleotide-mediated mechanisms [27]. To confirm our G-rich oligonu-
cleotides 17–24, which did not affect the aforementioned antisense machinery, they were 
mixed with lipofectamine 2000 and luciferase inhibition activities were evaluated after 24 
h-incubation as displayed in Figure 7. Interestingly, when analyzing the silencing activity 
of the oligonucleotides formed by Luc-TG4T (19) and Luc-TG6T (20) without any modifi-
cation at either 3′ or 5′, we found a clear decrease of the silencing activity when moving 
from a 4-Gs to a 6-Gs (91% and 62%, respectively) (Figure 7A). Curiously, this tendency is 
contrary to the stability of the potential quadruplex as the more stable quadruplex 
(Luc-TG6T (20)) displayed a reduced silencing activity. Thus, as this experiment was car-
ried out with a transfecting agent, the silencing activities exhibited by both antisense ol-
igonucleotides 19 and 20 cannot be explained based on their cellular uptake efficiencies, 
but other factors are needed to explain the lower antisense activity of the 6-Gs oligonu-
cleotide (20). For example, differences on the endosomal escape or in their efficiency in 
the binding process to target mRNA might also be taken into account. Next, we observed 
that the addition of the lipid at the 3′- improved the silencing activity on the 4-Gs oligo-
nucleotide (96% Luc-TG4T_C8 (15) and 95% Luc-TG4T_C14 (16) when compared to the 
6-Gs oligonucleotide counterparts (87% Luc-TG6T_C8 (17) and 82% Luc-TG6T_C14 (18)) 
(***p < 0.001). These data might give support to a more efficient endosomal escape rather 
than an increased binding affinity to target mRNA, but more experiments need to be 
done to confirm this hypothesis. Additionally, we observed that unmodified Luc-TG6T 
(20) was less efficient in silencing luciferase expression than their counterparts modified 
with lipid threoninol moieties Luc-TG6T_C8 (17) and Luc-TG6T_C14 (18) (62% versus 87% 
and 82%, respectively) (**p < 0.01 and *p < 0.05). These results may suggest the role of alkyl 
chains as well as the presence of threoninol moieties when conjugated covalently with 
oligonucleotides in order to favor endosomal escape or an increased binding affinity 
[33,53].  
The silencing efficiency of antisense G-rich oligonucleotides modified with lipids at 
the 5′-termini (C8_Luc-TG4T (21), C14_Luc-TG4T (22), C8_Luc-TG6T (23) and 
C14_Luc-TG6T (24)) was also studied (Figure 7B). The results showed lower silencing ac-
tivities of 5′-lipid conjugates when compared with their quadruplex counterparts modi-
fied at the 3′-termini (71%, 76%, 66% and 67% versus 96%, 95%, 87% and 82%, respec-
tively). This difference in silencing activities might be explained by differences in the 
degradation process mediated by nucleases including distinct quadruplex stabilities ob-
served in SDS-PAGE gels. Thus, when the lipid is at the 3′-end, oligonucleotide conju-
gates contain nuclease resistant moieties at both ends (3′-lipid; 5′-phosphorothioate), 
while when the lipid is added at the 5′-position, we have both nuclease resistance moie-
ties in line leaving the 3′-end of the oligonucleotide unprotected to exonucleases. Thus, it 
may be the 5′-lipid modified oligonucleotides that are prone to be degraded more rapidly 
if compared to the 3′-lipid modified oligonucleotides. Another potential reason may also 
be the low efficiency on G-quadruplex formation observed for the 5′-lipid modified oli-
gonucleotides (21–24). This may be another factor to increase nuclease degradation.  




Figure 7. Gene transfection studies targeting Renilla luciferase mRNA in the presence of Lipofectamine 2000 involving 
antisense G-quadruplex forming oligonucleotides 15–24 at 60 nM. Two series of conjugates containing four and six gua-
nines were studied. (A) antisense G-rich modified with lipid threoninol-based building blocks at the 3′-termini and (B) 
lipids were conjugated by modifying the 5′-termini of the G-rich oligonucleotide. Two alkyl chains were selected ac-
cording to their length (C8 and C14). Two unmodified G-rich oligonucleotides were used as controls (19 and 20). Data 
were means ±SD of three to six independent experiments. A regular two-way ANOVA variance analysis combined with 
Bonferroni post-test for multiple comparisons was evaluated (*p < 0.05, **p < 0.01 and ***p < 0.001). 
According to the silencing activities displayed above, we selected oligonucleotides 
15–18 as the most potent antisense constructs for further experiments. Gymnotic trans-
fection experiments using serum-free conditions remarkably reduced Renilla mRNA 
knockdown efficiencies when 15–18 constructs were used in the absence of lipofectamine 
(Figure 8A). Interestingly, silencing activities followed the same trend as observed in 
Figure 7A, in which constructs containing four Gs exhibited slightly better inhibition ac-
tivities (23% and 33% for 15 and 16, respectively) than G-rich constructs containing six Gs 
(19% and 20% for 17 and 18, respectively) at 600 nM. These outcomes revealed that long 
alkyl chains tended to interact more efficiently with the cellular membrane [54] by the 
inclusion of 16 and to a lesser extent 15- into phospholipid bilayers promoting their de-
stabilization and therefore leading to significant inhibition activities when compared to 
15 and 18 (*p < 0.05 and **p < 0.01, respectively). As expected, unmodified antisense G-rich 
constructs (19 and 20) were not able to inhibit luciferase in the same fashion that the 
modified nanostructures did (15% and 16%, respectively).  
Once the transfection process of conjugates was studied in serum-free conditions, 
dose-response experiments were then assessed to evaluate the effect of serum proteins on 
oligonucleotide delivery using four concentrations (60, 120, 300 and 600 nM). As shown 
in Figure 8B, all modified G-rich constructs (15–18), as well as unmodified G-rich coun-
terparts (19 and 20), were able to knockdown Renilla luciferase mRNA in a dose-response 
manner but with distinct effectiveness. Interestingly, the presence of serum proteins did 
not disrupt the transfection process of both unmodified and modified G-rich conjugates. 
According to Figure 7B, it is worth mentioning that oligonucleotide 15, which was made 
up of four potential G-quartets and a saturated alkyl chain of 8 atoms of carbons in 
length, showed the best silencing activity (36% of inhibition) of the two G-rich families, 
though these results were not considered statistically significant. Curiously, G-rich con-
structs modified with the long hydrophobic C14 alky chain (16) did not afford a greater 
increase in knocking down Renilla luciferase expression than the one observed in se-
rum-free conditions (22% versus 33%, respectively). This behavior underscores the role of 
serum proteins in promoting the transport of such nanostructures within cells. In this 
regard, experiments showed that certain saturated lipids tended to interact efficiently to 
albumin, which is the major component of serum, facilitating not only the formation of 
lipid-binding proteins complex, but also the delivery of oligonucleotide conjugates 
[55,56]. However, it was noted that this binding process was not as effective in the case of 
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interaction of such lipids to albumin and thereby could reduce the ability of G-rich se-
quence 16 to promote cell entry in some way.  
Remarkably, unmodified G-rich sequence 19 showed better and statistically signif-
icant silencing values than the unmodified G-rich sequence 16 containing six Gs (*p < 
0.05), as well as modified G-rich sequence 15 counterparts at high concentrations (300 
nM) (*p < 0.05). This effect was already observed previously [27] and revealed other pa-
rameters including receptor-mediated processes might be involved in promoting silenc-
ing of Renilla luciferase.  
 
Figure 8. Gene transfection studies targeting Renilla luciferase mRNA without using lipofectamine in serum-free condi-
tions (A). Modified and unmodified antisense conjugates (15–18) and (19, 20) were used at 600 nM. (B) Dose-response 
transfection experiments using several concentrations (60, 120, 300 and 600 nM) in the absence of lipofectamine. G4_(19, 
20) were used as controls. Data were means ±SD of three to six independent experiments. A regular two-way ANOVA 
variance analysis, combined with Bonferroni post-test for multiple comparisons, was evaluated (*p < 0.05 and **p < 0.01). 
2.5. Cellular Uptake Studies 
A fluorescently labeled F_G-rich_15 conjugate (25) and a F_T-rich (26) conjugate 
were prepared to carry out internalization studies in HeLa expressing nucleolin and 
human embryonic kidney (HEK293) cells. To do so, a phosphoramidite-based approach 
was used to introduce a fluorescein dye at the 5′-termini of phosphorothioate Luc oligo-
nucleotide. The ability of such constructs to transfect HeLa and HEK293 cell lines was 
evaluated by flow cytometry analysis. 
Figure 9A illustrates a histogram showing a remarkable displacement of fluores-
cently labeled HeLa cell populations (84%) when compared to non-treated cells after 
having been used in the G-rich sequence 25 at 300 nM. It was noted that the displacement 
of fluorescence HeLa cells was dependent on the concentration used, showing a smaller 
number of labelled cells at 60 nM (69%) (Figure 9B). In this regard, flow cytometry ex-
periments using the same concentration (60 nM) of the G-rich 25 construct was carried 
out in the presence of HEK293 cells (Figure 8B). Interestingly, the number of labelled 
HEK293 cells obtained after transfection was lower than in Figure 8A and dropped to 
16%, which might be an indication of the preference of G-rich sequence constructs for 
nucleolin receptors expressed in the surface of HeLa cells. To evaluate the affinity of 
G-rich sequence 25 on transfection, conjugate 26 containing the same threoninol modifi-
cations at the 3′-termini and a Luc oligonucleotide and fluorescein at 5′-termini of a T-rich 
sequence (TTTTTT) was prepared. Surprisingly conjugate 26 was able to impart cellular 
uptake with similar efficiencies and no statistically significant differences were found in 
HeLa cells when compared to G4_25 at two concentrations (60 and 300 nM) (Figure S3 
and Figure S4, Supplementary material). Despite molecular mechanisms involving oli-
gonucleotide uptake are not fully understood in some cases, the lack of selectivity we 
observed between G-rich and the T-rich conjugates might be justified due to the presence 
of phosphorothioate Luc oligonucleotide in both constructs. In this regard, phos-
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phorothioate oligonucleotides have shown to be prone to interact indistinctly to several 
binding proteins like albumin or nucleolin, among others, which might affect and com-
promise both the potency and subcellular location of such oligonucleotide conjugates in 
the cell culture line used in this study [58–60]. 
 
Figure 9. Flow cytometry analysis involving the effect of the G-rich sequence 25 when transfecting HeLa (A) and HEK293 
cells (B). (A) Transfections were carried using G-rich sequence 25 at 300 nM. First row: non-fluorescent labelled cell pop-
ulations (Blank); selected region R-2 (center) and histogram of non-fluorescent cells (right); second row: forward scatter 
dot plot (left) and histogram (right) of G-rich sequence 25 in the presence of HeLa cells at 300 nM. (B) Transfections were 
carried using G-rich sequence 25 at 60 nM. First row: non-fluorescent labelled cell populations (Blank); selected region 
R-2 (center) and histogram of non-fluorescent cells (right); second row: forward Scheme 25. and HEK293 cells; forward 
scatter dot plot (middle) using G-rich sequence 25 and HeLa cells and combined histogram (right) of G-rich sequence 25 
in the presence of HeLa and HEK293 cells at 60 nM. The Flowing Software 2.5.1 was used to measure the relationship 
between untreated cells and positive cell populations. 
2.6. Comparison of the Luciferase Inhibitory Properties of Antisense Oligonucleotides Carrying 
TG4T or T6 Sequences.  
The small differences observed on the cellular uptake of G-rich (25) and T-rich (26) 
oligonucleotides prompted us to analyze, side by side, if there was a difference in the lu-
ciferase inhibitory properties of these oligonucleotides. Figure 10 shows the luciferase 
activity of oligonucleotides 25 and 26 using lipofectamine 2000 as a transfecting agent in 
HeLa cells after 24 h of treatment. Here, we used lipofectamine 2000 to equally internalize 
compounds 25 (G-rich oligonucleotide), 26 (T-rich oligonucleotide) and the antisense lu-
ciferase oligonucleotide (Luc) at 60 nM. As illustrated in Figure 9, greater and significant 
inhibition of the G-rich oligonucleotide 25 was achieved if compared to the T-rich se-
quence 26 (*p < 0.05) and Luc oligonucleotide, as a control. 




Figure 10. Gene transfection studies targeting Renilla luciferase mRNA in the presence of Lipofec-
tamine 2000 involving antisense G-rich oligonucleotide 25 and two oligonucleotide controls: the 
T-rich 26 and the luc-sequence (ASO) at 60 nM. Two unmodified G-rich oligonucleotides were used 
as controls (19 and 20). Data were means ±SD of three to six independent experiments. A regular 
two-way ANOVA variance analysis combined with Bonferroni post-test for multiple comparisons 
was evaluated (*p < 0.05, **p < 0.01 and ***p < 0.001). 
This result shows a clear inhibitory advantage for the G-rich oligonucleotide. This 
increased efficacy might result from a positive contribution of the G-rich structure in the 
endosomal escape [61] and/or an increased efficacy of the oligonucleotide in the binding 
and subsequent RNase H degradation of target luciferase mRNA [62]. Next, we evalu-
ated the long-term silencing properties of these two oligonucleotides (25 and 26) and Luc 
oligonucleotide without using a transfecting reagent. Figure 11 shows the luciferase 
concentration obtained after treatment of HeLa cells with these oligonucleotides (60 nM) 
after 24, 48 and 72 h.  
 
Figure 11. Gene transfection studies targeting Renilla luciferase mRNA without using transfecting 
reagents involving antisense G-rich oligonucleotide 25 and two control oligonucleotides such as 
the T-rich 26 and the luc-sequence (ASO) at 60 nM. Data were means ±SD of three to six inde-
pendent experiments. A regular two-way ANOVA variance analysis combined with Bonferroni 
post-test for multiple comparisons was evaluated (*p < 0.05). 
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While the most active oligonucleotide was the standard anti-luciferase oligonucleo-
tide (Luc) after 24 h-incubation, it was probably due to its smaller size and was fully 
protected by a phosphorothioate backbone, and its efficacy decreased at longer times (72 
h). However, we observed that the G-rich oligonucleotide 25 became more active after 
enlarging the incubation time up to 72 h. In this sense, the T-rich oligonucleotide 26 had a 
similar trend than 25, but was much less active. Taking all these results together, we can 
conclude that the presence of the G-rich sequence increases the inhibitory properties of 
the antisense oligonucleotide but the advantage might be related with a potential im-
provement of the endosomal escape rather than the predicted increase of cellular uptake. 
More research needs to be done to confirm this interesting hypothesis.  
3. Materials and Methods  
3.1. General Methods and Materials 
All chemical reactions were carried out under inert atmosphere using anhydrous 
solvents and oven-dried glassware. Chemical reactions were stirred magnetically. 
Chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) and used directly 
without further purification. Analytical thin layer chromatography (TLC) was used to 
monitor all reactions. TLC plates (Alugram SilG/UV254) were visualized either under UV 
light or by staining with a phosphomolybdic acid solution. Flash chromatography was 
performed on 0.063–0.2 mm/70–230 mesh SDS silica gel.  
NMR spectra were carried out in the Nuclear Magnetic Resonance (NMR) core fa-
cility of the Institute for Advanced Chemistry of Catalonia (IQAC CSIC). 1H (400 MHz) 
and 13C (proton decoupled, 100 MHz) NMR spectra were obtained using a Varian Mer-
cury spectrometer (Agilent Technologies, Santa Clara, USA) at 25 C and referenced to 
residual signal (Tetramethylsilane, TMS; 0 ppm) and deuterated solvents like CDCl3 (7.26 
ppm and 77.16 ppm) for 1H and 13C NMR spectra, respectively. 1H NMR coupling con-
stant(s) are reported in hertz (Hz) for peak integration, whereas chemical shifts are re-
ported in part per million (ppm). Multiplicity is reported as follows: singlet (s), doublet 
(d), triplet (t), m (multiplet) and bs (broad signal). Electrospray ionization mass spec-
troscopy (ESI-MS) and high-resolution (HR) ESI-MS were carried out in the Scientific and 
Technological Centers of the Universitat del Barcelona. ESI-MS and HRESI-MS were per-
formed on a Micromass ZQ instrument (Milford, MA, USA) with a single quadrupole 
detector coupled to an HPLC and an Agilent 1100 LC/MS-TOF instrument (Santa Clara, 
CA, USA), respectively.  
Oligonucleotide synthesis was carried out in-house on an Applied Biosystem 3700 
instrument (Carlsbad, CA, USA) on a 1 μmol scale using the standard manufacturer’s 
protocol. Standard phosphoramidites (A, C, G and T), solid resins and ancillary reagents 
were purchased from Applied Biosystems (Carlsbad, CA, USA), Link Technologies 
(Lanarkshire, Scotland, UK) and/or Glen Research (Sterling, VA, USA). The isobutyryl 
(iBu) and benzoyl (Bz) groups were used to protect groups from guanosine (G) and the 
Adenosine (A) and Cytidine’s (C) amino groups, respectively. The coupling efficiency 
was greater than 95%. Fluorescent oligonucleotides were prepared using a commercially 
available 6-FAM phosphoramidite, which was purchased from Link Technologies (Lan-
arkshire, Scotland, UK). A commercially available 5′-carboxylate modifier-CE phospho-
ramidite (Carboxy-C5) was purchased from Link Technologies (Lanarkshire, Scotland, 
UK). Both unmodified and modified oligonucleotides were cleaved from the solid sup-
port using a concentrated ammonia solution (55 C, overnight) and desalted through a 
NAP-10 column by a gel-filtration (Sephadex G-25) (GE Healthcare) (Pittsburgh, PA, 
USA). All oligonucleotide conjugates were purified following DMTon-based protocols 
(80% AcOH in water; 30 min at room temperature). Unmodified oligonucleotides were 
deprotected following DMToff-based protocols (aq NH3 solution (32%), 55 C, overnight). 
Purity of crude samples were analyzed by RP-HPLC using a Waters 2695 Separation 
Module equipped with a Waters 2998 Photodiode Array Detector. Oligonucleotide con-
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jugates were purified using two buffers: 1. Buffer A: 5% ACN in 100 mM triethylammo-
nium acetate (TEAA; pH 7.0) and 2. Buffer B: 70% ACN in 100 mM triethylammonium 
acetate (TEAA; pH 7.0). Matrix-assisted laser desorption ionization-of-flight (MAL-
DI-TOF) mass spectra was used to identify the correct mass of the modified oligonucleo-
tides. MALDI-TOF mass spectra were recorded on a Voyager-DETMRP spectrometer in 
negative mode using 2,4,6-trihidroxyacetophenone and ammonium citrate as a matrix 
and additive, respectively. UV analyses were used to determine the oligonucleotide 
concentration (unmodified and modified). These analyses were carried out on a Jasco 
V-650 instrument equipped with a thermoregulated cell holder. Melting temperatures 
(Tm) were obtained using MATLAB routines (R2009b version; Math-Works, Natick, MA, 
USA).  
A phosphorothioate oligonucleotide sequence [44] 
[d(5′-CGTTTCCTTTGTTCTGGA-3′)] was synthesized in-house according to 
DMToff-based protocols. A commercially available cationic lipid (Lipofectamine2000) 
was purchased from Invitrogen (Waltham, MA, USA). DMEM-Dulbecco’s modified ea-
gle medium, trypsin-EDTA, fetal bovine serum (FBS) and distilled water (DNAse/RNAse 
free) were purchased from Thermo-Fischer (Waltham, MA, USA). DMEM-Dulbecco’s 
modified eagle medium was supplemented with 10% FBS, which was used in the ex-
periments involving cells. The dual-luciferase reporter assay system was purchased from 
Promega (Madison, WI, USA) and silencing values were measured in a Promega Glomax 
Multidetection System instrument. Flow cytometer analyses were performed on a Gua-
va® easyCyte 8HT instrument (Millipore; Burlington, MA, USA). Flowing software (ver-
sion 2.5.1, University of Turku, Finland) was used as a tool to perform flow cytometry 
data analysis.  
3.2. General Protocol for Derivatizing L-Threoninol with Fmoc-Lys(Boc)-OH 
Fmoc-Lys(Boc)-OH (500 mg; 1.07 mmol; 1.0 eq) and EDC (245 mg; 1,07 mmol; 1.2 eq) 
were mixed in dichoromethane (DCM; 3 mL) and stirred for 10 min at room temperature. 
N-hydroxysuccinimide (NHS) (136 mg; 1.18 mmol; 1.1 eq) was added and the final mix-
ture was stirred at room temperature overnight. The organic layer was washed with 
water (2 × 10 mL), brine (2 x 10 mL) and dried over anhydrous MgSO4. The solvent was 
evaporated to dryness and the resultant crude was used without further purification. 
NHS-lysine derivative (1) (605 mg; 1.07 mmol; 1.0 eq) was dissolved in dimethylforma-
mide (DMF; 3 mL) and L-threoninol (103 mg; 0.979 mmol; 1.1 eq) was added. The final 
solution was stirred overnight at room temperature. DMF was evaporated to dryness and 
the final crude was purified by flash chromatography (DCM:MeOH 4%) yielding the 
expected LTHR-Fmoc-Lys(Boc) (2; 75%).  
3.3. General Protocol for Derivatizing 1 with Alkyl Residues of Different Length (C8 and C14) 
L-threoninol derivative (2) (1.0 eq) was dissolved in an acid solution made up of 
DCM and trifluoroacetic acid (10%) at room temperature. The final solution was stirred 
for 30 min. The solvent was evaporated to dryness and the resultant trifluoroacetate salt 
derivative, which was used in the next step without further purification. The isolated salt 
(1.0 eq) was dissolved in tetrahydrofurane (THF) (2 mL) and triethylamine (TEA) (2.1 eq) 
was added. After stirring 10 min at room temperature, an aqueous solution of 50% w/v 
AcONa (2 mL) was added dropwise under vigorous stirring. Octanoyl chloride (1.1 eq) 
or myristoyl chloride (1.1 eq) were added dropwise and the resultant mixture was stirred 
at room temperature overnight. THF was evaporated to dryness and organic layers (5 mL 
of DCM) were washed with brine (3 x 10 mL). The organic layers were dried under an-
hydrous MgSO4 and solvents were reduced in vacuo. Final crudes were purified by flash 
chromatography (DCM:MeOH 1% to 4%), yielding the expected lipophilic derivatives 3 
(97%) and 4 (78%).  
(9H-fluoren-9-yl)methyl-(1-(((2R,3R)-1,3-dihydroxybutan-2-yl)amino)-6-octanamido
-1-oxohexan-2-yl)carbamate (3); 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 7.57 Hz, 2H), 
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7.56 (d, J = 7.56 Hz, 2H), 7.36 (t, J = 7.43 Hz, 2H), 7.26 (m, 2H), 6.92 (broad d, 1H; NH), 5.91 
(broad m, 2H; 2 NH), 4.33 (d, J = 7.21 Hz, 2H; CH2-OH), 4.23 (m, 1H; CH-OH), 4.16 (m, 
2H; CO-CH2-CH), 3.78 (m, 3H; CH2-NHCO- and CO-CH-NH-CO), 3.20 (m, 1H; 
CH2-CH-NH-), 2.10 (t, J = 7.46 Hz, 2H; CH2-CH2), 1.53 (m, 4H; alkyl chain), 1.23 (m, 12H; 
alkyl chain), 1.15 (d, J = 6.34 Hz, 3H; CH3-CH-OH), 0.84 (t, J = 6.67 Hz, 3H; CH3-CH2); 13C 
NMR (125 MHz, CDCl3) δ 174.3 (CO), 172.3 (CONH), 156,2 (COO), 143.8 (Carom), 143.7 
(Carom), 141.2 (CHarom), 127.7 (CHarom), 127.0 (CHarom), 125.0 (CHarom), 119.9 (CHarom), 68.8 
(HC-CH2-O), 67.0 (CH2-O), 64.6 (CH-O), 55.0 (OC-CH-NH), 47.1 (CH2-NH), 47.0 
(CH2-CO), 39.4 (CH-NH), 38.6 (CH2, alkyl chain), 36.7 (CH2, alkyl chain), 32.3 (CH2, alkyl 
chain), 31.6 (CH2, alkyl chain), 29.3 (CH2, alkyl chain), 29.1 (CH2, alkyl chain), 28.9 (CH2, 
alkyl chain), 25.7 (CH2, alkyl chain), 22.5 (CH2, alkyl chain), 22.2 (CH2, alkyl chain), 20.2 
(CH3-CH), 14.0 (CH3-CH2); HRMS (ESI+): m/z calcd for C66H95N6O12 [(2M+H)+] 1163.7009 
found 1163.7002.  
(9H-fluoren-9-yl)methyl-(1-(((2R,3R)-1,3-dihydroxybutan-2-yl)amino)-6-octanamido
-1-oxo-6-tetradecanamidohexan-2-yl)carbamate (4); 1H NMR (400 MHz, CDCl3) δ 7.73 (d, 
J = 7.51 Hz, 2H), 7.58 (d, J = 7.42 Hz, 2H), 7.37 (t, J = 7.44 Hz, 2H), 7.28 (m, 2H), 6.90 (broad 
d, 1H; NH), 5.83 (broad m, 2H; 2 NH), 4.35 (d, J = 7.01 Hz, 2H; CH2-OH), 4.18 (m, 3H; 
CO-CH2-CH and CH-OH), 3.80 (m, 3H; CH2-NHCO- and CO-CH-NH-CO), 3.09 (m, 5H; 
CH2-NH, CH-NH and CH2-CO), 2.30 (broad s), 2.13 (t, J = 7.98 Hz, 2H; CH2-CH2), 1.34 (t, J 
= 7.28 Hz, 2H; CH2-CH2), 1.22 (m, 22H; alkyl chain), 1.14 (d, J = 6.09 Hz, 3H; CH3-CH-OH), 
0.85 (t, J = 6.69 Hz, 3H; CH3-CH2); 13C NMR (125 MHz, CDCl3) δ 174.4 (CO), 172.1 (CO), 
143.8 (Carom), 143.7 (Carom), 141.2 (CHarom), 127.7 (CHarom), 127.0 (CHarom), 125.1 (CHarom), 
119.9 (CHarom), 69.2 (HC-CH2-O), 67.0 (CH2-O), 65.0 (CH-O), 54.8 (OC-CH-NH), 47.0 
(CH2-NH), 45.7 (CH-NH), 39.2 (OC-CH2, alkyl chain), 38.5 (CH2, alkyl chain), 36.7 (CH2, 
alkyl chain), 32.2 (CH2, alkyl chain), 31.8 (CH2, alkyl chain), 29.6 (CH2, alkyl chain), 29.4 
(CH2, alkyl chain), 29.2 (CH2, alkyl chain), 25.7 (CH2, alkyl chain), 22.6 (CH2, alkyl chain), 
20.2 (CH2, alkyl chain), 14.0 (CH3-CH), 8.5 (CH3-CH2); HRMS (ESI+): m/z calcd for 
C39H59N3NaO6 [(M+Na)+] 688.4294 found 688.4296; m/z calcd for C78H118N6NaO12 
[(2M+Na)+] 1353.8704 found 1353.8700. 
3.4. General Protocol for A Selective Primary Alcohol Protection Using A Trityl Unit as A 
Protecting Group 
Alcohol derivatives (3) and (4) (1.0 eq, each) and DMAP (0.5 eq) were dissolved in 
pyridine (1.0 mL). DIPEA (2.0 eq) was added dropwise. Reactions were stirred 5 min at 
room temperature and trityl chloride (TrCl) (1.6 eq) was added. Reactions were heated at 
45 ℃and stirred overnight. Additional TrCl (0.5 eq) was added so that the remaining al-
cohols reacted completely. Reactions were stirred one more hour at room temperature. 
Finally, the solvent was evaporated to dryness and the resulting crudes were purified by 
flash chromatography (DCM to DCM:MeOH 4%), yielding the expected trityl derivatives 
5 (24%) and 6 (53%).  
(9H-fluoren-9-yl)methyl-(1-(((2R,3R)-3-hydroxy-1-(trityloxy)butan-2-yl)amino)-6-oct
anamido-1-oxohexan-2-yl)carbamate (5); 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.57 Hz, 
2H), 7.56 (d, J = 7.21 Hz, 2H), 7.49 (d, J = 7.50 Hz, 2H), 7.37 (m, 7H), 7.26 (m, 8H), 7.21 (m, 
2H), 6.78 (broad d, NH), 5.65 (broad d, NH), 5.55 (broad m, NH), 4.31 (d, J = 7.03 Hz, 2H; 
CO-CH2-CH), 4.19 (m, 1H; CH-OH), 4.13 (m, 1H; CH-OH), 4.01 (m, 1H; CH-OH), 3.92 (m, 
2H; CO-CH2-CH), 3.38 (m, 1H; CO-CH-NH-CO), 3.19 (m, 3H; CH2-NHCO- and CH-NH), 
2.07 (t, J = 7.44 Hz, 2H; CH2-CH2), 1.54 (m, 4H; alkyl residue), 1.39 (m, 2H; alkyl residue), 
1.22 (m, 10H; alkyl residue); 1.07 (d, J = 6.36 Hz, 3H; CH3-CH), 0.83 (t, J = 6.58 Hz, 3H; 
CH3-CH2); 13C NMR (125 MHz, CDCl3) δ 173.4 (CO), 172.0 (CO), 156.4 (COO), 143.3 (Car-
om), 141.2 (Carom), 128.4 (CHarom), 127.9 (CHarom), 127.6 (CHarom), 127.2 (CHarom), 127.0 
(CHarom), 125.1 (Carom), 125.0 (Carom), 119.9 (CHarom), 119.8 (CHarom), 87.1 (Cq), 68.2 
(HC-CH2-O), 67.1 (CH2-O), 64.6 (CH-O), 53.8 (OC-CH-NH), 47.0 (CH2-NH), 38.5 
(OC-CH2, alkyl chain), 36.8 (CH2, alkyl chain), 32.0 (CH2, alkyl chain), 31.6 (CH2, alkyl 
chain), 29.2 (CH2, alkyl chain), 28.9 (CH2, alkyl chain), 25.7 (CH2, alkyl chain), 22.6 (CH2, 
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alkyl chain), 22.5 (CH2, alkyl chain), 19.9 (CH3-CH), 14.0 (CH3-CH2); HRMS (ESI+): m/z 
calcd for C52H61N3NaO6 [(M+Na)+] 846.4460 found 846.4453.  
(9H-fluoren-9-yl)methyl-(1-(((2R,3R)-3-hydroxy-1-(trityloxy)butan-2-yl)amino)-6-tet
radecanamidohexan-2-yl)carbamate (6); 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.58 Hz, 
2H), 7.56 (d, J = 7.51 Hz, 2H), 7.48 (m, 2H), 7.36 (m, 7H), 7.26 (m, 8H), 7.20 (m, 2H), 6.83 
(broad d, 1H; NH), 5.70 (broad d, 1H; NH), 5.57 (broad m, 1H; NH), 4.32 (m, 2H; 
CO-CH2-CH), 4.20 (m, 1H; CH-OH), 4.12 (m, 1H; CH-OH), 4.01 (m, 1H; CH-OH), 3.92 (m, 
2H; CO-CH2-CH), 3.37 (m, 1H; CO-CH-NH-CO), 3.19 (m, 3H; CH2-NHCO- and CH-NH), 
2.07 (t, J = 7.40 Hz, 2H; CH2-CH2), 1.70 (m, 2H), 1.52 (m, 6H), 1.37 (m, 2H), 1.21 (m, 16H), 
1.05 (d, J = 6.33 Hz, 3H; CH3-CH), 0.86 (t, J = 6.67 Hz, 3H; CH3-CH2); 13C NMR (125 MHz, 
CDCl3) δ 173.4 (CO), 172.1 (CO), 156.4 (COO), 143.3 (Carom), 141.2 (Carom), 128.4 (CHarom), 
127.9 (CHarom), 127.6 (CHarom), 127.4 (CHarom), 127.3 (Carom), 127.0 (CHarom), 125.0 (Carom), 
119.9 (CHarom), 87.0 (Cq), 68.1 (HC-CH2-O), 67.1 (CH2-O), 64.6 (CH-O), 53.9 (OC-CH-NH), 
47.0 (CH2-NH), 38.6 (OC-CH2, alkyl chain), 36.8 (CH2, alkyl chain), 31.8 (CH2, alkyl chain), 
29.7 (CH2, alkyl chain), 29.6 (CH2, alkyl chain), 29.4 (CH2, alkyl chain), 29.3 (CH2, alkyl 
chain), 29.0 (CH2, alkyl chain), 25.7 (CH2, alkyl chain), 22.6 (CH2, alkyl chain), 19.9 
(CH3-CH), 14.0 (CH3-CH2); HRMS (ESI+): m/z calcd for C58H73N3NaO6 [(M+Na)+] 930.5440 
found 930.54423; m/z calcd for C116H147N6O12 [(2M+H)+] 1816.1045 found 1816.1072.  
3.5. General Protocol for CPG Functionalization and DNA Synthesis 
Trityl derivatives (1.0 eq), succinic anhydride (1.5 eq) and DMAP (1.5 eq) were dis-
solved in DCM (1.5 mL). The resultant solution was stirring at room temperature over-
night. The organic layer was washed with a 0.5M phosphate solution. The organic layer 
was dried over anhydrous MgSO4 and the resultant hemisuccinate crudes were used in 
the next step without further purification. Finally, CPG functionalization was carried out 
according to the literature [43], affording the corresponding CPG-7 and CPG-8, respec-
tively. 3′-DNA synthesis was carried out and enabled the introduction of three distinct 
sequences: (1) d(TGGGGT; TG4T), (2) d(TGGGGGGT; TG6T) and (3) a 18-mer phos-
phorothioate oligonucleotide of sequence 5-CGTTTCCTTTGTTCTGGA-3 (Luc) which 
modified the 5′-termini of (1) and (2). After heating up the corresponding CPG solid 
supports at 55 ℃ in aqueous ammonia, unmodified oligonucleotides and families of 
oligonucleotide conjugates modified with lipids were isolated and purified by 
semi-preparative HPLC: (1) unmodified d(TGGGGT; TG4T, 9) and d(TGGGGGGT; TG6T, 
10) oligonucleotides; (2) oligonucleotide conjugates modified with lipids at the 3′-termini; 
TG4T_C8 (11), TG4T_C14 (12), TG6T_C8 (13) and TG6T_C14 (14), and (3) Lipid oligonu-
cleotide antisense conjugates; Luc_TG4T_C8 (15), Luc_TG4T_C14 (16), Luc_TG6T_C8 (17) 
and Luc_TG6T_C14 (18) as well as Luc_TG4T (19) and Luc_TG6T (20), which were used as 
controls in transfection experiments. 
3.6. General Protocol for Introducing Aminolipids on Solid-Phase 
CPG solid supports containing d(TGGGGT) and d(TGGGGGGT) as building blocks 
were modified with the Luc oligonucleotide sequence. A protected carboxylate modifier 
phosphoramidite with 2-chlorotrityl as a protecting group (Carboxy-C5) was automati-
cally introduced by modifying the 5′-termini of the final sequence giving rise to the fol-
lowing sequences: (1) d(5-carboxylate-Luc-TGGGGT-3) and (2) 
d(5-carboxylate-Luc-TGGGGGGT-3). The 2-chlorotrityl protecting group was removed 
from using a 2% TCA solution and the resultant carboxylate group was activated with a 
mixture based on PyBOP (20 μmol) and HOBt (20 μmol) using DMF as an organic sol-
vent. After 30 min at 35℃ TEA (20 μmol) and the selected amino lipids either (octylamine 
or tetradecylamine; 20 μmol each) in DMF were put in contact with the solid supports. 
Modified CPG resins were then shaked for two hours at 35 ℃ and finally washed with 
500 μL of DMF, MeOH and Et2O. 5′-LOC were detached from the CPG solid supports in 
accordance with the same experimental protocols described above obtaining the follow-
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ing conjugates: 5′_C8_Luc_TG4T (21), 5′_C14_Luc_TG4T (22), 5′_C8-Luc_TG6T (23) and 
5′_C14-Luc_TG6T (24). 
3.7. General Protocol for the G-Quadruplex Formation 
Unmodified and modified G-quadruplex nanostructures were prepared from the 
corresponding lyophilized oligonucleotides described in Section 2.5. Unmodified and 
modified oligonucleotide conjugates (9–24) were dissolved either in 10mM lithium cac-
odylate buffer (pH 7.2) supplemented with 0.11M NaCl or 10 mM phosphate buffer so-
lution (pH 7.4) depending on the experiment to afford the expected G-quadruplex 
nanostructures [G4-(9–24)]. Final solutions were heated up at 95 ℃ for 5 min and slowly 
cooled down to room temperature. Tempered solutions were remained for five days at 
room temperature and finally stored at -20 ℃ before usage. The following G-quadruplex 
nanostructures were obtained: (i) unmodified G4_9 and G6_10; (ii) G-quadruplex form-
ing oligonucleotide conjugates modified at the 3′-termini with two lipid derivatives, 
3′_G4_C8 (11), 3′_G4_C14 (12), 3′_G6_C8 (13), 3′_G6_C14 (14); (iii) G-quadruplex forming 
oligonucleotide conjugates bearing an antisense oligonucleotide (Luc) at the 5′-termini: 
5′_Luc_G4_C8 (15), 5′_Luc_G4_C14 (16), 5′_Luc_G6_C8 (17), 5′_Luc_G6_C14 (18), Luc_G4 
(19) and Luc_G6 (20) and (iv) G-quadruplex forming oligonucleotide conjugates with the 
5′-termini of Luc sequence modified with two saturated lipids of different lengths (C8 and 
C14, respectively): 5′_C8_Luc_G4 (21), 5′_C14_Luc_G4 (22), 5′_C8_Luc_G6 (23) and 
5′_C14_Luc_G6 (24).  
3.8. CD Spectroscopy and Melting Experiments 
The CD spectra of unmodified G-quadruplexes [d(TG4T)]4 and [d(TG6T)]4 (1.0 OD), 
as well as modified G-quadruplexes [G4-(9–14)] (1.0 OD), were registered, ranging from 
220 and 320 nm at 25 ºC in the appropriate buffer (10 mM sodium cacodylate buffer, pH 
7.2, supplemented with 0.11M NaCl). CD thermal denaturation experiments were carried 
out using a selected range of temperatures between 20 and 80 ºC and a heating rate of 
either 1 or 5.0 ℃ min−1. The corresponding CD values were monitored at 263 nm. 
3.9. Electromobility Shift Assay 
A native polyacrylamide gel electrophoresis (PAGE) was carried out using acryla-
mide concentrations of 20% and 12% (v/v) to characterize quadruplex structures (9–25) 
dissolved in PBS. A 20% PAGE gel was carried out in order to identify the different nu-
cleic acid structures made up of 6 to 8 nucleotides (Figure 5A). On the other hand, a 12% 
PAGE gel was used for the characterization of larger oligonucleotides (Figure S1). 1X TBE 
buffer supplemented with 100 mM KCl was used to run the gels at 100V (20% PAGE) and 
150V (12% PAGE) for approximately 4–5 h, maintaining a fixed temperature of 20 ºC. A 
“stains-all” solution (0,001% dissolved in a mixture of formamide/H2O (45 mL/55 mL)) 
was used to stain a PAGE 20% gel for 20 min at room temperature. Finally, a picture of 
the gel was taken under white light. For the 12% PAGE gels, SYBR green (20 μL in 200 μL 
1X TBE) was used to stain the DNA bands and then pictures were taken using Fujifilm 
LAS-1000 Intelligent Dark Box II as well as IR LAS-1000 Lite v1.2. In both cases, the lad-
der used was a solution containing Bromophenol Blue and Xylene Cyanol for visual 
tracking of oligonucleotides migration during the electrophoretic process. 
3.10. Fluorescence Spectroscopy Experiments 
Modified G-quadruplexes [G4_(11–14)] as well as unmodified [G4_9 and G6_10], 
were dissolved in 10 mM phosphate buffer solution (pH 7.4) to obtain a final concentra-
tion of 69 nM. Fluorescence was registered using a wavelength ranging from 450–650 nm 
at room temperature (RT). A benzothiazole salt, like Thioflavin T (ThT), was used as 
fluorescence dye that interacts with the pre-formed tetrads and turns out an emission 
peak at the λ = 490–492 nm after ThT was sequentially added to the sample solution 
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[48,49]. This technique is a visual tool to determine the presence of parallel G-quadruplex 
secondary conformation on some DNA sequences. 
3.11. MTT Assay 
Cytotoxicity experiments were studied according to the literature [52]. Cellular via-
bilities were carried out on a 96-well plate in HeLa cells (5·103 cells/well), which were 
incubated in DMEM (200 μL) at 37 ℃. Both oligonucleotide conjugates (15–24) and 
G-quadruplex forming oligonucleotides [G4_(15–24)] were incubated at growing con-
centrations (60, 120 and 300 nM) for 24 h. DMEM was removed and wells were replaced 
with fresh DMEM (200 μL). Cells were incubated 4 more hours and MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was added (25 μL; 5 
mg·mL−1). After 2 h of incubation, the medium was discharged, and formazan crystals 
were dissolved in DMSO (200 μL). The resulting solutions were shaken for 15 min at 
room temperature and cellular viability was registered at 570 nm. G4_19 and G4_20 were 
used as negative controls. Normalized data displayed the relationship between treated 
and non-treated cells. Cytotoxicity studies were carried out six times in two independent 
experiments.  
3.12. Gene Transfection Studies 
Cancerous cervical cells (HeLa) were passaged in order to maintain exponential 
growth. HeLa cells were seeded (105 cells/well) and incubated at 37 ºC in a 24-well plate 
to get 60% confluence using DMEM supplemented with 10% FBS. Two different trans-
fection experiments were carried out: (i) in the presence and (ii) in the absence of 
lipofectamine.  
3.12.1. Transfection Studies in the Presence of Lipofectamine 
In the first case, Renilla (pRL-TK; 0.1 μg) and Firefly (pGL4; 1.0 μg) luciferase were 
used as reporter and control plasmids, respectively. These plasmids were combined ei-
ther with oligonucleotide conjugates (15–24) or G4-forming oligonucleotide conjugates 
[G4_(15–24)] at 60 nM and lipofectamine (1.3 μL) in Opti-MEM. The resultant formula-
tion was added to each well resulting in a final volume of 600 μL. Liposomes were in-
cubated for 15 h at 37 ºC. DMEM was removed and cells were washed with PBS. Finally, 
luciferase expression was measured according to the manufacturer’s protocol. Transfec-
tion experiments were carried out in triplicate in three independent experiments. Luc 
oligonucleotide, G4_19 and G4_20 were used as negative controls. The same experi-
mental protocol was carried out as described above when G-quadruplex forming oligo-
nucleotide 25 and T-rich oligonucleotide 26 were used at the same concentration (60 nM).  
3.12.2. Transfection Studies in the Abscene of Lipofectamine 
Renilla (pRL-TK; 0.1 μg) and Firefly (pGL4; 1.0 μg) luciferase were previously for-
mulated in liposomes using lipofectamine (1.3 μL) in Opti-MEM according to standard 
protocols. After 4 h of incubation, DMEM was removed and cells were washed with PBS 
(2 × 300 μL). Different concentrations of G-quadruplex forming oligonucleotides (15–24) 
were prepared (60, 120 and 300 nM) and used for the transfection process in 600 μL of 
DMEM. After being the samples incubated for 24 h, DMEM was removed and wells were 
thoughtfully with PBS (3 × 300 μL). Luciferase expression was measured according to the 
manufacturer’s protocol. Transfection experiments were carried out in triplicate in three 
independent experiments. Luc oligonucleotide, G4_19 and G4_20 were used as negative 
controls. The same experimental protocol was carried out, as described above when 
G-quadruplex forming oligonucleotide 25 and T-rich oligonucleotide 26 were used at the 
same concentration (60 nM). 
3.13. Flow Cytometry 
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HeLa cells (105 cells/well) were seeded in a 24-well plate the day before. Transfection 
experiments were performed according to the experimental procedure described before. 
A fluorescently labelled G4-quaduplex forming oligonucleotide conjugate was used at a 
concentration of 300 nM to promote a transfection process in the absence of lipofec-
tamine. The number of positive cells was analyzed after 24 h incubation. DMEM was 
removed and cells were firstly washed with PBS (3 × 300 μL) and then 200 μL of 
EDTA-Trypsin were added. Cells containing trypsin were incubated at 37 ℃ for 5 min. 
DMEM was added (800 μL) and trypsinized cells were centrifuged ((3.0 rcf x 3 min), 8 
min). Cellular pellets were suspended in PBS (500 μL) and analyzed using a flow cy-
tometer instrument and collecting 104 events in a selected gate (R1), which corresponds to 
the cellular population. A second gate (R2) was selected to evaluate the number of posi-
tive cells of each transfection process. The Flowing Software 2.5.1 developed by the 
University of Turku (Finland) was used to measure the relationship between untreated 
cell and positive cell populations. 
3.14. Statistical Analysis 
For in vitro transfections of G-quadruplex forming oligonucleotide conjugates, a 
2-way ANOVA analysis combined with the Bonferroni post-test was used for studying 
statistical differences. 
4. Conclusions 
The use of covalent strategies has been addressed to modify either the 3′- or 
5′-termini of a G-rich sequence with a threoninol-based scaffold containing two saturated 
lipids with different lengths and a phosphorothioate (Luc) oligonucleotide, respectively. 
In addition, another family of G-rich lipid oligonucleotide conjugates was prepared by 
solid-phase strategies involving a carboxylate modifier and two amino lipids, namely 
octylamine and tetradecylamine. After the preparation of the two series of lipid oligonu-
cleotide conjugates, G-rich sequences were self-assembled in phosphate saline buffer to 
give rise to the corresponding modified G-quadruplex constructs. Interestingly, the 
presence of modifications introduced at the 3′-termini of nanostructures containing both 
four and six G-quartets did not disrupt the G-quadruplex stability causing their melting 
temperature (T1/2) to increase. Unfortunately, the addition of the antisense oligonucleo-
tide to the G-quadruplexes disrupts the G-quadruplex stability, as observed by the 
presence of two bands in gel electrophoresis especially for the TG4T and the 5′-modified 
sequences. 
Those modified conjugates made up of Luc oligonucleotide and hydrophobic pen-
dent groups were not toxic and proved to be efficient in knocking down mRNA Renilla 
luciferase when combined with a commercially available cationic lipid. Remarkably, the 
conjugates containing four G-quartets and modified with 3′-threoninol pendent groups 
were the most potent constructs of the two antisense families prepared in this study. 
Transfection experiments carried out in the absence of lipofectamine revealed moderate 
inhibition activities when targeting Renilla luciferase being the oligonucleotides 19 and 15 
the most efficient antisense constructs of our series. The presence of binding proteins in 
serum like albumin, among others might be responsible for favoring the cell entry of such 
oligonucleotides. To confirm the affinity of conjugates to potential receptors present in 
cancer cells, flow cytometry analysis using HeLa and HEK293 cells were performed. As 
expected, a significant amount of fluorescently labelled cell populations was obtained 
when transfecting HeLa cells with oligonucleotide 25, but also with a control T-rich oli-
gonucleotide. Although we could not confirm the potential use of G-rich oligonucleotides 
in the enhancement of cell uptake of antisense oligonucleotides, additional studies will be 
performed with G-rich oligonucleotides to deliver not only short nucleic acids but other 
important therapeutic cargoes like small molecule drugs that may not interfere with 
G-quadruplex formation. 
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